Uncategorized

BioInvent International AB announces the appointment of Ingunn Munch Lindvig as Senior Vice President Regulatory Affairs.

Veristat, a scientific-minded global clinical research organization and regulatory consultancy, shared the addition of three seasoned leaders to Veristat’s Executive team.

TISSIUM announced it has closed a Series D round of financing, raising €50 million from new and existing international investors, including Fonds Stratégique des Transitions, managed by ISALT, Merieux Developpement and returning Cathay Health, Credit Mutuel Innovation and Sofinnova Partners.

Innate Pharma SA announced that members of its senior management team are scheduled to participate in the following upcoming conferences.

Guardant Health, Inc., a leading precision oncology company, announced the pricing of an upsized underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $28.00 per share, before deducting underwriting discounts and commissions.

Agile Therapeutics, Inc., a women’s healthcare company, announced the pricing of its public offering of an aggregate of 1,896,286 shares of its common stock, together with accompanying common stock warrants, at a public offering price of $3.9551 per share and accompanying warrants.

Propanc Biopharma, Inc., a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced that the Company’s board of directors has approved a reverse stock split of its common stock at a ratio of 1 post-split share for every 1,000 pre-split shares.

Data from a Phase III trial of apraglutide for a type of short bowel syndrome with intestinal failure is expected by the end of the year. It is also in a Phase II study for acute graft-versus-host disease.

Los pasos básicos para su abordaje en Atención Primaria y Emergencias

A series of recent innovations in pacemaker technology have opened up new markets and set the stage for increased competition.